NCT02828397View on ClinicalTrials.gov

Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

REGN2222

Trial Locations (2)

Unknown

Daytona Beach

Evansville

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02828397 - Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects | Biotech Hunter | Biotech Hunter